Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer
- 17 December 2010
- journal article
- Published by Wiley in Histopathology
- Vol. 57 (6), 885-892
- https://doi.org/10.1111/j.1365-2559.2010.03725.x
Abstract
To examine the immunohistochemical expression and function of ribonucleotide reductase M2 subunit (RRM2), a gemcitabine-related molecule, in bladder cancer. One hundred and seventeen bladder specimens on a tissue microarray were immunostained for RRM2. Positive RRM2 staining was observed in none of 14 examples of non-neoplastic urothelium, none of four low-grade urothelial carcinoma (UC), 69 of 83 (83%) high-grade UC, three of three (100%) squamous cell carcinoma and 12 of 13 (92%) lymph node metastasis of UC. RRM2 overexpression was associated significantly with muscularis propria invasion in UC patients who had undergone radical cystectomy (P=0.005). Immunohistochemistry for RRM2 was then applied to small biopsy specimens of 15 cystitis with reactive atypia cases and 25 urothelial carcinoma in-situ (CIS) cases. Positive RRM2 staining was found in one of 15 (6.7%) cystitis with reactive atypia cases and in 24 of 25 (96%) CIS cases. Finally, UM-UC-3 bladder cancer cells were transfected with RRM2 siRNAs and cell growth was evaluated. Knockdown of RRM2 protein markedly inhibited cell growth. We have shown frequent overexpression of RRM2 protein and its possible role in bladder cancer. Our results suggest that RRM2 is a novel diagnostic marker and a potential therapeutic target in bladder cancer.Keywords
This publication has 29 references indexed in Scilit:
- Clinical pharmacology and pharmacogenetics of gemcitabineDrug Metabolism Reviews, 2009
- Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium StudyCancer Chemotherapy and Pharmacology, 2009
- Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesisMolecular Cancer, 2009
- Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumorsCancer Chemotherapy and Pharmacology, 2008
- Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabineBritish Journal of Cancer, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2Experimental & Molecular Medicine, 2008
- Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomasThe Esophagus, 2007
- RRM2 induces NF-κB-dependent MMP-9 activation and enhances cellular invasivenessBiochemical and Biophysical Research Communications, 2007
- Agarose Cell Block: Innovated Technique for the Processing of Urine Cytology for Electron Microscopy ExaminationUltrastructural Pathology, 2004